IN THE SPECIFICATION:

The specification has been objected to because the application incorrectly referred itself as a continuation-in-part of a provisional application (Examiner's Action #7(a)). Please amend the first paragraph of the specification to state that the instant application claims priority to the provisional application SN 60/097,120, filed 08/19/1998.

The specification has been objected to (Examiner's Action #7(b))due to the recitations of trademarks without the use of full-capitalization and generic terminology. Please amend the specification as requested below:

On page 17, please replace or rewrite line 24 to read as follows:

-- the miniDAWN® (Wyatt Technology Corp., Santa Barbara, CA) --

On page 18, please rewrite line 22 to read as follows:

-- 1.6x60cm column of SUPERDEX™ 200 PG (Pharmacia) and eluted with PBS containing --

On page 19, please rewrite line 19 to read as follows:

-- deionized water. After diafiltration through an AMICON™ YM3 membrane with deionized --

On page 20, please rewrite line 6 to read as follows:

-- N HCL. The solution was diafiltrated with an AMICON™ YM3 membrane in a stircell --

On page 20, please rewrite line 13 and line 14 to read as follows:

-- ZWITTERGEN™ 3,14 (Boehringer Mannheim) pH 9.5 was incubated at 37°C for 3 days. The conjugate was purified by size exclusion chromatography through a SUPERDEX™ 200 --

On page 20, please rewrite line 30 to read as follows:

B10 NE

-- chloride and 0.05% ZWITTERGEN™ 3-14 and loaded onto a PHARMACIA™ PD-10 desalting --

On page 21, please rewrite line 1 to read as follows:

B11 NE

-- AMICON™ Centricon® 30 concentrator at 5,000 RPM for one hour. The retentate was –

On page 21, please rewrite line 9 to read as follows:

B12 NE (Lived Ltr.) 09/28/02

-- SUPERDEX™ 200 column (Pharmacia) with PBS as eluant. UV-280-nm-active --

Not entered as of 09/28/02

On page 22, please rewrite lines 28 and 29 to read as follows:

B13 NE

-- hour at 37°C, followed by a PBS-TWEEN™ (0.05% v/v TWEEN™ 20 in PBS) was (5 times). All subsequent incubations were conducted at room temperature. PBS-TWEEN™ --

On page 23, please rewrite line 9 to read as follows:

B14 NE

-- well, and the plate was read on a MOLECULAR DEVICES™ Emax® microplate reader –

The specification is objected to because the abbreviation "DCC" is not understood (Examiner's Action #7(d)). Therefore, on page 9, please replace line 1 to read as follows:

B15 NE

-- acryloyl anhydride, acrylic acid and a dehydrating agent such as dicyclohexylcarbodiimide (DCC), $CH_2CHCOCN$ –